GlassScriptPhysician profile
Kofi Doonquah
NPI 1740210426
$9,398.91
in general payments reported to CMS, 2019-2025
73 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,286 · 2020: $1,309 · 2021: $2,234 · 2022: $2,125 · 2023: $937 · 2024: $331 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,245 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.39 |
| Education | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $893.70 | 2019-2024 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $530.89 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $521.96 | 2019-2024 | Ultomiris, Soliris |
| Abbvie INC. | $441.32 | 2021-2023 | Vraylar, Botox, Qulipta |
| Amgen INC. | $412.84 | 2019-2023 | Aimovig |
| Ucb, INC. | $388.45 | 2019-2023 | Briviact, Nayzilam |
| Sunovion Pharmaceuticals INC. | $283.95 | 2019-2022 | |
| Pfizer INC. | $264.27 | 2019-2025 | |
| Adamas Pharmaceuticals, INC. | $239.27 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $225.32 | 2020-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $202.92 | 2020-2023 | Vyepti |
| Neurocrine Biosciences, INC. | $202.60 | 2019-2023 | Ingrezza, Ongentys |
| Biodelivery Sciences International, INC. | $188.39 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $181.72 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $179.71 | 2019-2022 |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kofi Doonquah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.